Moderna to present Phase 3 adjuvant melanoma data at ESMO
Moderna said late-breaking Phase 3 data for intismeran autogene in adjuvant melanoma will be presented at an ESMO 2026 Presidential Symposium. An investor webcast is scheduled for Oct 24.
Moderna said late-breaking Phase 3 data for intismeran autogene in adjuvant melanoma will be presented at an ESMO 2026 Presidential Symposium. An investor webcast is scheduled for Oct 24.